FDA accepts Supplemental New Drug Application for secnidazole for treatment of trichomoniasis

Application is based on a phase III placebo-controlled RCT which demonstrated microbiological cure, defined as a negative trichomonas vaginalis culture, in the modified intent-to-treat (92.2% vs 1.5%; p<0.001) and per-protocol populations (94.9% vs 1.7%; p<0.001).

Source:

Biospace Inc.